Case Snapshot
Full name | Ron K. Elfenbein, M.D. |
|---|---|
Display name | Dr. Ron Elfenbein |
Home state | Maryland |
Federal district | District of Maryland, Baltimore |
District court case | United States v. Elfenbein, 1:22-cr-00146-JKB-1 |
Appellate / Supreme Court | United States v. Elfenbein, No. 24-4048, 144 F.4th 551 (4th Cir. 2025); Elfenbein v. United States, No. 25-574 |
Type of case | Criminal / health care fraud / COVID-19 billing |
Disposition | Jury conviction August 4, 2023; judgment of acquittal December 21, 2023; acquittal reversed and new trial order affirmed July 17, 2025; certiorari denied |
Sentence | No sentence imposed; retrial pending |
Current status | Awaiting retrial in the District of Maryland after Supreme Court review was denied |
Core WW issue | Whether a criminal fraud prosecution based on disputed CPT coding interpretations provided fair notice and sufficient safeguards, and whether the unusual procedural history warrants heightened public review |
Case Overview
A federal grand jury in Maryland indicted emergency physician Ron Elfenbein in April 2022 in connection with billing at Drs ERgent Care, an urgent-care business that expanded heavily into COVID-19 testing during the pandemic. The case ultimately proceeded to trial on five counts of health care fraud, each tied to a patient visit for COVID-19 testing.
The government alleged that Elfenbein caused insurers to be billed for high-level evaluation-and-management visits that were not provided as represented. The disputed visits were billed using Level 4 CPT codes. Elfenbein maintained that the coding rules permitted his interpretation and that the care provided supported the claims. The case therefore turns not only on intent, but also on whether the billing representations were objectively false.
After an 11-day trial, a jury convicted Elfenbein on all five counts on August 4, 2023. On December 21, 2023, Judge James K. Bredar granted a judgment of acquittal, concluding that the government had not presented evidence from which a reasonable jury could find that the disputed statements were beyond a reasonable doubt. The court also conditionally granted a new trial, finding that the weight of the evidence was heavily against the verdict.
On July 17, 2025, the Fourth Circuit reversed the judgment of acquittal, holding that the evidence was legally sufficient for a jury to convict, but affirmed the district court’s conditional order granting a new trial. The appellate court described the case as closed and noted the unusual fact that much of the most damaging evidence emerged during the defense case rather than the government’s case-in-chief. The Supreme Court denied certiorari on December 15, 2025. Elfenbein is awaiting retrial in the District of Maryland.
Why Weaponization Watch Supports This Case
Weaponization Watch does not treat the district court’s acquittal as a final declaration that the prosecution was improper, and the Fourth Circuit held that the jury had legally sufficient evidence to convict. The government has a legitimate responsibility to prosecute knowingly false medical claims and protect public health programs from fraud.
Weaponization Watch supports careful, transparent review of this case because its procedural history is extraordinary: the trial judge who heard the evidence entered a judgment of acquittal and separately found a new trial necessary, while the Fourth Circuit later reinstated the prosecution but agreed that a new trial was warranted. The case raises broader questions about when a disputed interpretation of complex medical billing rules becomes criminal fraud, what level of clarity is required before criminal liability attaches, and how prosecutors should exercise discretion when professional organizations responsible for the coding system support the defense position. Elfenbein and his supporters also contend that the prosecution followed his public criticism of federal COVID-19 policy. That timing does not by itself establish retaliation, but the allegation is appropriate for documented, nonpartisan review.
Key Public-Interest Questions
When CPT billing rules permit competing interpretations, what proof should be required to establish that a claim was objectively false rather than merely disputed or incorrectly coded?
What weight should be given to the trial judge’s conclusion that no reasonable jury could find falsity beyond a reasonable doubt, even though the Fourth Circuit later found the evidence legally sufficient?
Why did the Fourth Circuit reverse the acquittal yet affirm the district court’s separate determination that the interests of justice required a new trial?
What significance should courts give to the American Medical Association and Maryland State Medical Society appearing as amici in support of Elfenbein in a case centered on CPT coding rules?
Did the jury receive sufficiently clear instructions to distinguish a good-faith billing interpretation from knowing health care fraud?
What evidence, if any, supports the claim by Elfenbein and his supporters that his public criticism of federal monoclonal-antibody policy played a role in the charging decision?
At retrial, what safeguards will ensure that disputed coding judgments, medical necessity, documentation practices, and criminal intent are evaluated separately and clearly?
Case Documentation Note
The government maintains that Elfenbein knowingly caused false claims for high-level office visits to be submitted to Medicare and other insurers in connection with COVID-19 testing, and a jury convicted him on five counts. The Fourth Circuit concluded that the trial evidence was legally sufficient to support those verdicts. Weaponization Watch is not declaring Elfenbein innocent or asserting retaliatory prosecution as an established fact. This case file documents the unusual acquittal-and-retrial history, the dispute over CPT coding ambiguity and falsity, the participation of major medical organizations as amici, and the public-interest questions surrounding a renewed federal prosecution.
Timeline
Date / Period | Event |
|---|---|
April 19, 2022 | A federal grand jury returned an indictment charging Elfenbein with health care fraud in the District of Maryland. The case later proceeded to trial on five counts. |
August 4, 2023 | After an 11-day trial, a jury convicted Elfenbein on five counts of health care fraud. |
December 21, 2023 | The district court granted judgment of acquittal and conditionally granted a new trial in the event the acquittal was reversed. |
January 19, 2024 | The United States filed its notice of appeal from the district court ruling. |
July 17, 2025 | The Fourth Circuit reversed the judgment of acquittal but affirmed the conditional order granting a new trial and remanded the case. |
November 10, 2025 | Elfenbein filed a petition for a writ of certiorari in the Supreme Court, docketed as No. 25-574. |
December 15, 2025 | The Supreme Court denied certiorari. |
Key Concerns
Key Concerns
Ambiguous coding rules and criminal falsity
The district court concluded that the government had not proved the disputed Level 4 billing statements false beyond a reasonable doubt, while the Fourth Circuit held that the jury could reasonably resolve the competing interpretations against Elfenbein. That disagreement makes the line between billing error, negligent overbilling, and criminal fraud central to the case.
Acquittal followed by retrial
The trial judge not only granted judgment of acquittal but also conditionally ordered a new trial. The Fourth Circuit reversed the acquittal under the deferential standard governing jury verdicts, yet agreed that the district court did not abuse its discretion in finding a new trial was warranted. The result leaves Elfenbein facing a second trial after a judge who observed the first one found the evidence insufficient and heavily against the verdict.
Medical-profession amicus support
The American Medical Association and the Maryland State Medical Society appeared as amici supporting Elfenbein in the Fourth Circuit. Their participation does not decide guilt or innocence, but it underscores the broader concern that unclear or evolving coding standards can create criminal exposure for physicians.
Government case versus defense evidence
The Fourth Circuit emphasized that the case was close and found it significant that much of the strongest evidence supporting conviction came during the defense case. That unusual posture raises important questions about how the government’s burden of proof should be evaluated at retrial.
Alleged retaliation for protected speech
Elfenbein and supporters contend that the prosecution followed his public criticism of federal COVID-19 policy, including policy concerning monoclonal antibodies. The existing judicial decisions reviewed for this file do not establish retaliatory motive. Weaponization Watch supports examining the chronology and relevant records without treating political retaliation as a proven fact.
Retrial and prosecutorial discretion
With the Supreme Court declining review, the case returns to the district court for another trial. The government retains authority to prosecute conduct it believes constitutes fraud, but the prior acquittal ruling, the affirmed new-trial order, the coding dispute, and the professional amicus support make the exercise of prosecutorial discretion a legitimate public-interest issue.
Why This Case Matters
Health care fraud law must punish knowingly false billing without turning reasonable disagreement over complex coding rules into a felony. When falsity depends on a technical standard, fair notice and a clear distinction between error and fraud are essential due-process safeguards.
This case also presents an unusual sequence: a jury convicted, the trial judge acquitted and ordered a new trial, and the Fourth Circuit reinstated the prosecution while agreeing that a new trial was warranted. That history, together with the coding dispute and the retaliation allegation, makes transparent review of the retrial and charging decisions important beyond one physician.
Document Vault
Document | Source / Description |
|---|---|
District Court Acquittal / New Trial Opinion | United States v. Elfenbein, 708 F. Supp. 3d 621 (D. Md. 2023). |
Fourth Circuit Opinion | United States v. Elfenbein, 144 F.4th 551 (4th Cir. 2025). |
AMA / Maryland State Medical Society Amicus Brief | Fourth Circuit amicus brief supporting Elfenbein on the medical-coding issues. |
Supreme Court Docket | Elfenbein v. United States, No. 25-574; certiorari denied December 15, 2025. |
